TORONTO, ONTARIO--(Marketwired - May 13, 2015) - Spectral Medical Inc., (TSX:EDT)(OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock that comprises a therapeutic device guided by a companion diagnostic, today announced its unaudited financial results for the first quarter ended March 31, 2015.
Financial Review
Revenue for the three months ended March 31, 2015 was $877,000 compared to $844,000 for the same period in the preceding year. First quarter revenues were consistent with prior year levels and this trend is expected to continue for the remainder of the year.
Operating costs for the quarter ended March 31, 2015 amounted to $3,166,000 compared to $4,033,000 in 2014. The $867,000 decrease is almost entirely attributable to lower costs for the EUPHRATES trial, resulting from fewer new sites being initiated into the trial and lower patient enrolment after the implementation of an additional exclusion criterion in April, 2014 that refined patient selection. Apart from clinical trial activities, the Company continues to maintain a low cost operating structure for its base business operations.
Loss for the quarter ended March 31, 2015 was $2,265,000 ($0.01 per share) compared to $3,175,000 ($0.02 per share) for the same quarter last year.
The Company concluded the first quarter of 2015 with cash and cash equivalents of $7,068,000 compared to $10,054,000 cash and cash equivalents on hand as of December 31, 2014.
On April 1, 2015, the Company closed Tranche B of its financing for $6,110,000 bringing the cash balance to $13,178,000.
The total number of shares outstanding for the Company was 179,755,741 as at March 31, 2015.
About Spectral
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of endotoxemic septic shock. Toraymyxin ™ (PMX) is a therapeutic hemoperfusion device that removes endotoxin, a main trigger of sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study for a medical device in the area of septic shock.
PMX has been approved for therapeutic use in Japan and Europe, and has been used on more than 100,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 350,000 patients are diagnosed with septic shock in North America each year, representing a greater than $3 billion market opportunity for Spectral.
Spectral is listed on the Toronto Stock Exchange under the symbol EDT, and on the OTCQX under the symbol EDTXF. For more information please visit www.spectraldx.com.
Forward-looking statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
| Spectral Medical Inc. |
|
|
|
|
| Condensed Interim Statements of Financial Position |
|
|
|
|
| |
|
|
|
|
| (in thousands of Canadian dollars) |
|
|
|
|
| |
|
|
|
|
| |
March 31 2015 |
|
December 31 2014 |
|
| |
$ |
|
$ |
|
| |
|
|
|
|
| Assets |
|
|
|
|
| Current assets |
|
|
|
|
| Cash and cash equivalents |
7,068 |
|
10,054 |
|
| Trade and other receivables |
675 |
|
583 |
|
| Inventories |
218 |
|
166 |
|
| Prepayments |
234 |
|
185 |
|
| |
8,195 |
|
10,988 |
|
| Non-current assets |
|
|
|
|
| Property and equipment |
571 |
|
490 |
|
| Intangible asset |
378 |
|
384 |
|
| |
949 |
|
874 |
|
| |
|
|
|
|
| Total assets |
9,144 |
|
11,862 |
|
| |
|
|
|
|
| Liabilities |
|
|
|
|
| Current liabilities |
|
|
|
|
| Trade and other payables |
2,411 |
|
2.893 |
|
| Deferred revenue |
85 |
|
149 |
|
| Total liabilities |
2,496 |
|
3,042 |
|
| |
|
|
|
|
| Equity |
|
|
|
|
| Share capital |
46,931 |
|
46,879 |
|
| Contributed surplus |
7,826 |
|
7,849 |
|
| Other equity reserves |
3,606 |
|
3,542 |
|
| Deficit |
(51,715 |
) |
(49,450 |
) |
| Total equity |
6,648 |
|
8,820 |
|
| |
|
|
|
|
| Total liabilities and equity |
9,144 |
|
11,862 |
|
| |
|
|
|
|
| Spectral Medical Inc. |
| Condensed Interim Statement of Loss and Comprehensive Loss |
| For the three months ended March 31, 2015 and 2014 |
| (Unaudited) |
| |
| (in thousands of Canadian dollars, except for share and per share data) |
| |
|
|
|
|
| |
2015 |
|
2014 |
|
| |
$ |
|
$ |
|
| |
|
|
|
|
| Revenue |
877 |
|
844 |
|
| |
|
|
|
|
| Expenses |
|
|
|
|
| Changes in inventories of finished goods and work- in-process |
24 |
|
173 |
|
| Raw materials and consumables used |
100 |
|
77 |
|
| Employee benefits |
947 |
|
1,034 |
|
| Consulting and professional fees |
1,572 |
|
2,287 |
|
| Regulatory and investor relations |
170 |
|
76 |
|
| Travel and entertainment |
203 |
|
179 |
|
| Depreciation and amortization |
43 |
|
64 |
|
| Foreign exchange (gain) loss |
(17 |
) |
27 |
|
| Other expenses |
124 |
|
116 |
|
| |
3,166 |
|
4,033 |
|
| |
|
|
|
|
| Operating loss |
(2,289 |
) |
(3,189 |
) |
| |
|
|
|
|
| Finance income |
24 |
|
14 |
|
| |
|
|
|
|
| Loss and comprehensive loss for the period |
(2,265 |
) |
(3,175 |
) |
| |
|
|
|
|
| Basic and diluted loss per common share |
(0.01 |
) |
(0.02 |
) |
| |
|
|
|
|
| Weighted average number of common shares outstanding |
179,750,247 |
|
134,462,580 |
|
| |
|
|
|
|
| Spectral Medical Inc. |
|
| Condensed Interim Statements of Changes in Equity |
|
| For the three months ended March 31, 2015 and 2014 |
|
| (Unaudited) |
|
| |
|
| (In thousands of Canadian dollars) |
|
| |
|
|
|
|
|
|
|
|
|
|
|
| |
Issued capital |
|
Contributed surplus |
|
Share-based compensation |
|
Warrants |
Deficit |
|
Total Equity |
|
| |
Number |
|
$ |
|
$ |
|
$ |
|
$ |
$ |
|
$ |
|
| Balance, January 1, 2014 |
134,462,561 |
|
33,957 |
|
3,864 |
|
3,239 |
|
4,594 |
(39,958 |
) |
5,696 |
|
| Warrants exercised |
46 |
|
- |
|
- |
|
- |
|
- |
- |
|
- |
|
| Loss and comprehensive loss for the period |
- |
|
- |
|
- |
|
- |
|
- |
(3,175 |
) |
(3,175 |
) |
| Share-based compensation |
- |
|
- |
|
- |
|
205 |
|
- |
- |
|
205 |
|
| Balance, March 31, 2014 |
134,462,607 |
|
33,957 |
|
3,864 |
|
3.444 |
|
4,594 |
(43,133 |
) |
2,726 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Balance, January 1, 2015 |
179,737,241 |
|
46,879 |
|
7,849 |
|
3,542 |
|
- |
(49,450 |
) |
8,820 |
|
| Shares repurchased under the normal course issuer bid |
(90,000 |
) |
(32 |
) |
(23 |
) |
- |
|
- |
- |
|
(55 |
) |
| Share options exercised |
108,500 |
|
84 |
|
- |
|
(41 |
) |
- |
- |
|
43 |
|
| Loss and comprehensive loss for the period |
- |
|
- |
|
- |
|
- |
|
- |
(2,265 |
) |
(2,265 |
) |
| Share-based compensation |
- |
|
- |
|
- |
|
105 |
|
- |
- |
|
105 |
|
| Balance, March 31, 2015 |
179,755,741 |
|
46,931 |
|
7,826 |
|
3,606 |
|
- |
(51,715 |
) |
6,648 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Spectral Medical Inc. |
|
| Condensed Interim Statements of Cash Flows |
|
| For the three months ended March 31, 2015 and 2014 |
|
| (Unaudited) |
|
| |
|
| (In thousands of Canadian dollars) |
|
| |
|
|
|
|
| |
2015 |
|
2014 |
|
| |
$ |
|
$ |
|
| Cash flow provided by (used in) |
|
|
|
|
| |
|
|
|
|
| Operating activities |
|
|
|
|
| Loss and comprehensive loss for the year |
(2,265 |
) |
(3,175 |
) |
| Adjustments for: |
|
|
|
|
| |
Depreciation on property and equipment |
37 |
|
58 |
|
| |
Amortization of intangible asset |
6 |
|
6 |
|
| |
Share-based compensation |
105 |
|
205 |
|
| Changes in items of working capital: |
|
|
|
|
| |
Trade and other receivables |
(92 |
) |
(104 |
) |
| |
Inventories |
(52 |
) |
126 |
|
| |
Prepayments |
(49 |
) |
(54 |
) |
| |
Trade and other payables |
(482 |
) |
(533 |
) |
| |
Deferred revenue |
(64 |
) |
(26 |
) |
| Net cash used in operating activities |
(2,856 |
) |
(3,497 |
) |
| |
|
|
|
|
| Investing activities |
|
|
|
|
| Property and equipment expenditures |
(118 |
) |
(2 |
) |
| Net cash used in investing activities |
(118 |
) |
(2 |
) |
| |
|
|
|
|
| Financing activities |
|
|
|
|
| Share options exercised |
43 |
|
- |
|
| Shares repurchased under the NCIB |
(55 |
) |
- |
|
| Net cash used in financing activities |
(12 |
) |
- |
|
| |
|
|
|
|
| Decrease in cash and cash equivalents |
(2,986 |
) |
(3,499 |
) |
| |
|
|
|
|
| Cash and cash equivalents, beginning of period |
10,054 |
|
7,229 |
|
| Cash and cash equivalents, end of period |
7,068 |
|
3,730 |
|